STOCKHOLDERS' EQUITY

3 Months Ended

May 31, 2020

Equity [Abstract]

STOCKHOLDERS' EQUITY

NOTE 12 – STOCKHOLDERS’ EQUITY

Stock-based compensation expense is included in the following captions of the condensed consolidated statements of comprehensive income (loss) (in thousands):

	Three Months Ended
	May 31,
	2020		2019
Cost of revenues	$	175	$	175
Research and development		646		413
Selling and marketing		505		669
General and administrative		1,422		1,286
Restructuring		875		-
	$	3,623	$	2,543

Changes in our outstanding stock options during the three months ended May 31, 2020 were as follows (options in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted average remaining contractual life (years)		Aggregate intrinsic value
Outstanding at February 29, 2020		1,071		$	14.65		6.2
Granted		—			—
Exercised		(10	)		2.34
Forfeited or expired		(49	)		21.57
Outstanding at May 31, 2020		1,012		$	14.44		5.9	$	463
Exercisable at May 31, 2020		623		$	13.38		4.5	$	463

Changes in our outstanding restricted stock shares, performance stock units (“PSUs”) and restricted stock units (“RSUs”) during the three months ended May 31, 2020 were as follows (restricted shares, PSUs and RSUs in thousands):

	Number of Restricted Shares, PSUs and RSUs			Weighted Average Grant Date Fair Value		Shares Retained to Cover Statutory Minimum Withholding Taxes
Outstanding at February 29, 2020		2,215		$	14.47
Granted		89			7.61
Vested		(34	)		15.93		13
Forfeited		(135	)		13.90
Outstanding at May 31, 2020		2,135		$	14.19

As of May 31, 2020, there was $19.1 million of total unrecognized stock-based compensation cost related to outstanding nonvested equity awards that is expected to be recognized as an expense over a weighted-average remaining vesting period of 3.6 years.